![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
As the subject of active research and development (R&D) in recent decades, monoclonal antibodies have emerged among the major classes of therapeutic agents for treatment of many human diseases, especially cancers, infections, and immunological disorders. This article surveys the landscape of R&D projects of therapeutic monoclonal antibodies (mAbs), which are mostly used for disease immunotherapy, from a number of perspectives, including therapeutic indications, development phases, participants, and citation of related patents. The results of this research can be used as a reference resource for pharmaceutical researchers, investors, and policymakers in the field of therapeutic mAbs
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Supplemental Material
Supplemental data for this article can be accessed on the publisher's website.
Note
aIndications of mAb-related R&D programs were classified for simplicity into six therapeutic categories (anti-cancer, immunological, anti-infective, neuropharmacological, cardiovascular and cerebrovascular, and others). Anti-cancer indications included mAbs for treating various types of cancers; anti-infective indications included mAbs against viral infection, bacterial infection, or fungal infection; immunological indications were assigned to mAbs as a treatment for transplant rejection, inflammation, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or several other autoimmune diseases.
Funding
We thank the University of Macau for financial support for this research by the project MYRG2015-00172-ICMS-QRCM.